BMS sets unified research and development structure for 2027
The new structure will unify the company's scientific and clinical expertise, covering both discovery and development.
Drug Development
Takeda begins US distribution of narcolepsy type 1 drug Orzeyful
FDA and EMA waive paediatric studies for Shanton’s gout candidate
Litmys and PharmaACE partner on pharma commercial forecasting
ProBio signs global antibody licensing deal with AbTis
Lilly-backed Oyster Therapeutics raises $60m for neurological degraders
Delix Therapeutics raises $100m for zalsupindole development
Charles River agrees $470m deal for Frontage assets
